                         SEQUENCE LISTING

<110>  Singapore Health Services Pte. Ltd.
 
<120>  Chimeric antigen receptors and modified cells comprising the 
       same

<130>  53174317

<150>  10202104940X
<151>  2021-05-11

<160>  166   

<170>  PatentIn version 3.5

<210>  1
<211>  238
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a TNF-alpha scFv clone P3H2

<400>  1

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Ser Ser Thr Gly Ala Ser Thr Thr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Gly Gly Ala Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
        115                 120                 125             


Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala 
    130                 135                 140                 


Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile 
145                 150                 155                 160 


Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys 
                165                 170                 175     


Leu Leu Ile Tyr Ser Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg 
            180                 185                 190         


Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 
        195                 200                 205             


Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Asn 
    210                 215                 220                 


Ala Pro Thr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
225                 230                 235             


<210>  2
<211>  714
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  An exemplary coding sequence for the TNF-alpha scFv clone P3H2

<400>  2
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc       60

tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt ccgccaggct      120

ccagggaagg ggctggagtg ggtctcaagt atttcttcta ctggtgcttc tacaacttac      180

gcagactccg tgaagggcag gttcaccatc tccagagaca attccaagaa cacgctgtat      240

ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaaggtggt      300

gctgcttttg actactgggg ccagggaacc ctggtcaccg tcagcagcgg tggaggtggt      360

tctggtggag gaggttctgg tggcggtggt tctgacatcc agatgaccca gtctccatcc      420

tccctgtctg catctgtagg agacagagtc accatcactt gccgggcaag tcagagcatt      480

agcagctatt taaattggta tcagcagaaa ccagggaaag cccctaagct cctgatctat      540

agtgcatcct atttgcaaag tggggtccca tcaaggttca gtggcagtgg atctgggaca      600

gatttcactc tcaccatcag cagtctgcaa cctgaagatt ttgcaactta ctactgtcaa      660

caggctaata atgctcctac tacgttcggc caagggacca aggtggaaat caaa            714


<210>  3
<211>  246
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of an IFN-gamma scFv TII 6AE52

<400>  3

Glu Val Lys Leu Glu Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Met His Trp Ile Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Tyr Pro Gly Ile Ser Asp Thr Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Val Lys Ala Lys Leu Thr Ala Val Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Asp Glu Asp Phe Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
        115                 120                 125             


Gly Gly Gly Gly Ser Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu 
    130                 135                 140                 


Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln 
145                 150                 155                 160 


Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln 
                165                 170                 175     


Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg 
            180                 185                 190         


Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 
        195                 200                 205             


Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr 
    210                 215                 220                 


Tyr Cys Phe Arg Gly Ser His Ala Pro Tyr Thr Phe Gly Gly Gly Thr 
225                 230                 235                 240 


Lys Leu Glu Ile Lys Arg 
                245     


<210>  4
<211>  738
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  An exemplary coding sequence for the IFN-gamma scFv TII 6AE52

<400>  4
gaggtcaagc tggagcagtc tgggactgtg ctggcaaggc ctggggcttc agtgaagatg       60

tcctgcaagg cttctggcta cacctttacc aactactgga tgcattggat aagacagagg      120

cctggacagg gtctggaatg gattggcgct atttatcctg gaattagtga tactagttac      180

aaccagaagt tcaaggtcaa ggccaaactg actgcagtca catccaccag cactgcctac      240

atggagctca gcagcctgac aaatgaggac tctgcggtct attattgtac aagagatgag      300

gatttcgacg gctttgctta ctggggccaa gggactctgg tcactgtctc tgcaggtggt      360

ggtgggtctg gcggaggtgg tagtggaggt ggtgggtctg atgttttgat gacccaaact      420

ccactctccc tgcctgtcag tcttggagat caagcctcca tctcttgcag atctagtcag      480

agtattgtac atagtaatgg aaacacctat ttagactggt acctgcagaa accaggccag      540

tctccaaagc tcctgatcta caaagtttcc aaccgatttt ctggggtccc agacaggttc      600

agtggcagtg gatcagggac agatttcaca ctcaggatca gcagagtgga ggctgaggat      660

ctgggagttt attactgctt tcgaggatca catgctccgt acacgttcgg aggggggacc      720

aagctggaaa taaaacgg                                                    738


<210>  5
<211>  243
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence of IFN-gamma scFv TII 2G1G7

<400>  5

Gln Val Lys Leu Glu Gln Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Arg Asp Gly Asn Arg Tyr Tyr Thr Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Ala Ser Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Glu Asn Val Leu Thr Gln Ser Pro Ala Ile 
    130                 135                 140                 


Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 
145                 150                 155                 160 


Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly 
                165                 170                 175     


Gly Ser Pro Lys Leu Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly 
            180                 185                 190         


Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu 
        195                 200                 205             


Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln 
    210                 215                 220                 


Gln Tyr Ser Gly Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu 
225                 230                 235                 240 


Leu Lys Arg 
            


<210>  6
<211>  729
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  An exemplary coding sequence for the IFN-gamma scFv TII 2G1G7

<400>  6
caagttaagc tggagcagtc aggacctggc ctggtggcgc cctcacagag cctgtccatc       60

acttgcactg tctctgggtt ttcattaacc agctatggtg tacactgggt tcgccagtct      120

ccaggaaagg gtctggagtg gctgggagta atatgggctg gtggaagcac aaattataat      180

tcggctctca tgtccagact gagcatcagt aaagacaact ccaagagcca agttttctta      240

aaaatgaaca gtctgcaaac tgatgacaca gccatgtact actgtgccag aagagatggt      300

aacaggtact atactatgga ctactggggt caaggagctt cagtcaccgt ctcctcaggt      360

ggtggtgggt ctggcggagg tggtagtgga ggtggtgggt ctgaaaatgt gctcacccag      420

tctccagcaa tcatgtctgc atctccaggg gaaaaggtca ccatgacctg cagggccagc      480

tcaagtgtaa gttccagtta cttgcactgg taccagcaga agtcaggtgg ctcccccaaa      540

ctctggattt atagaacatc caacttggct tctggagtcc ctgctcgctt cagtggcagt      600

gggtctggga cctcttactc tctcacaatc agcagtgtgg aggctgaaga tgctgccact      660

tattactgcc agcagtacag tggttacccg ctcacgttcg gtgctgggac caagctggag      720

ctgaaacgg                                                              729


<210>  7
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a CD28 hinge

<400>  7

Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 
1               5                   10                  15      


Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 
            20                  25                  30          


Phe Pro Gly Pro Ser Lys Pro 
        35                  


<210>  8
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of an intracellular signalling 
       domain of CD3 zeta

<400>  8

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 
1               5                   10                  15      


Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 
            20                  25                  30          


Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 
        35                  40                  45              


Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 
    50                  55                  60                  


Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 
65                  70                  75                  80  


Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 
                85                  90                  95      


Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 
            100                 105                 110         


<210>  9
<211>  41
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of the co-stimulatory intracellular
       signalling domain of CD28

<400>  9

Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 
1               5                   10                  15      


Pro Arg Arg Leu Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 
            20                  25                  30          


Pro Arg Asp Phe Ala Ala Tyr Arg Ser 
        35                  40      


<210>  10
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a CD28 transmembrane domain

<400>  10

Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 
1               5                   10                  15      


Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 
            20                  25          


<210>  11
<211>  1380
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Exemplary coding sequence of a CAR comprising IFN-gamma scFv TII 
       2G1G7, a IgG4 hinge region, a CD28 transmembrane domain, a CD28 
       co-stimulatory domain, and a CD3 zeta signalling domain

<400>  11
atggctttgc ctgtgactgc actgttgctt cccttggctc tgcttctcca tgctgctaga       60

ccgcaagtta agctggagca gtcaggacct ggcctggtgg cgccctcaca gagcctgtcc      120

atcacttgca ctgtctctgg gttttcatta accagctatg gtgtacactg ggttcgccag      180

tctccaggaa agggtctgga gtggctggga gtaatatggg ctggtggaag cacaaattat      240

aattcggctc tcatgtccag actgagcatc agtaaagaca actccaagag ccaagttttc      300

ttaaaaatga acagtctgca aactgatgac acagccatgt actactgtgc cagaagagat      360

ggtaacaggt actatactat ggactactgg ggtcaaggag cttcagtcac cgtctcctca      420

ggtggtggtg ggtctggcgg aggtggtagt ggaggtggtg ggtctgaaaa tgtgctcacc      480

cagtctccag caatcatgtc tgcatctcca ggggaaaagg tcaccatgac ctgcagggcc      540

agctcaagtg taagttccag ttacttgcac tggtaccagc agaagtcagg tggctccccc      600

aaactctgga tttatagaac atccaacttg gcttctggag tccctgctcg cttcagtggc      660

agtgggtctg ggacctctta ctctctcaca atcagcagtg tggaggctga agatgctgcc      720

acttattact gccagcagta cagtggttac ccgctcacgt tcggtgctgg gaccaagctg      780

gagctgaaac gggctagcgc agaaagcaag tatggtcctc cctgcccccc gtgcccattt      840

tgggtgctgg tggtggttgg gggagtcctg gcttgctata gcttgctagt aacagtggcc      900

tttattattt tctgggtgag gagtaagagg agcaggctcc tgcacagtga ctacatgaac      960

atgactccaa gacgcctagg tcccactcgc aagcattacc agccctatgc cccaccacgc     1020

gacttcgcag cctatcgctc cagagtgaag ttcagcagga gcgcagacgc tccagcttac     1080

cagcagggcc agaaccagct ctataacgag ctcaatctag gacgaagaga ggagtacgat     1140

gttttggaca agagacgtgg ccgggaccct gagatggggg gaaagccgag aaggaagaac     1200

cctcaggaag gcctgtacaa tgaactgcag aaagataaga tggcggaggc ctacagtgag     1260

attgggatga aaggcgagcg ccggaggggc aaggggcacg atggccttta ccagggtctc     1320

agtacagcca ccaaggacac ctacgacgcc cttcacatgc aggccctgcc ccctcgctaa     1380


<210>  12
<211>  481
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of CAR PMC882 comprising the TNF 
       alpha scFv, a CD28 hinge, a CD28 transmembrane domain, a CD28 
       co-stimulatory domain, and a CD3 zeta signalling domain (with 
       leader sequence)

<400>  12

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 
1               5                   10                  15      


His Ala Ala Arg Pro Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu 
            20                  25                  30          


Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe 
        35                  40                  45              


Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys 
    50                  55                  60                  


Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Thr Gly Ala Ser Thr Thr 
65                  70                  75                  80  


Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser 
                85                  90                  95      


Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr 
            100                 105                 110         


Ala Val Tyr Tyr Cys Ala Lys Gly Gly Ala Ala Phe Asp Tyr Trp Gly 
        115                 120                 125             


Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 
    130                 135                 140                 


Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 
145                 150                 155                 160 


Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 
                165                 170                 175     


Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 
            180                 185                 190         


Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Tyr Leu Gln Ser 
        195                 200                 205             


Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
    210                 215                 220                 


Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 
225                 230                 235                 240 


Gln Gln Ala Asn Asn Ala Pro Thr Thr Phe Gly Gln Gly Thr Lys Val 
                245                 250                 255     


Glu Ile Lys Ala Ser Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu 
            260                 265                 270         


Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His 
        275                 280                 285             


Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val 
    290                 295                 300                 


Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr 
305                 310                 315                 320 


Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu 
                325                 330                 335     


His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Leu Gly Pro Thr Arg 
            340                 345                 350         


Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg 
        355                 360                 365             


Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln 
    370                 375                 380                 


Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu 
385                 390                 395                 400 


Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly 
                405                 410                 415     


Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln 
            420                 425                 430         


Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu 
        435                 440                 445             


Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr 
    450                 455                 460                 


Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro 
465                 470                 475                 480 


Arg 
    


<210>  13
<211>  1958
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Exemplary coding sequence of an NFAT-inducible expression 
       cassette, encoding a 6(NFAT) minimal IL-2 promoter, a TGF-beta 
       gene, a T2A peptide separating the TGF-beta and IL-10, and an 
       IL-10 gene

<400>  13
ggaggaaaaa ctgtttcata cagaaggcgt ggaggaaaaa ctgtttcata cagaaggcgt       60

ggaggaaaaa ctgtttcata cagaaggcgt ggaggaaaaa ctgtttcata cagaaggcgt      120

ggaggaaaaa ctgtttcata cagaaggcgt ggaggaaaaa ctgtttcata cagaaggcgt      180

cagaattaac agtataaatt gcatctcttg ttcaagagtt ccctatcact cgagcggtcg      240

ccaccatgcc accttctgga ctgcggttgc ttccgttgct gttgccactg ctttggctgc      300

ttgttctgac acctggcaga cccgcagccg gtttgtcaac atgcaaaacg atcgacatgg      360

agctggtaaa gcgcaagcgc attgaggcaa tcagagggca gatcttgagc aagcttcggc      420

tcgcctctcc tccaagccag ggcgaggtgc cacccggtcc gctgccggaa gcggttctcg      480

ctctctataa cagcactaga gatagggtcg caggtgagtc tgctgaacct gaacctgaac      540

cggaagctga ctattacgct aaagaggtga cgagagttct catggtggaa actcacaatg      600

agatttatga taaatttaaa cagtctaccc acagcattta tatgtttttt aacaccagtg      660

agctccgcga ggctgtccct gaacctgtcc tcctttccag ggcagaattg cggcttctga      720

ggctgaagct taaagtagag caacacgtgg agctctacca gaaatatagt aataacagct      780

ggagatatct gtcaaaccga ctgctggcgc cctccgacag tccagagtgg ctttcctttg      840

acgttactgg cgtggtgcgg caatggcttt caagaggcgg ggaaatcgag ggcttcaggc      900

ttagcgctca ctgctcatgt gatagtaggg ataacacact tcaggtagac attaatgggt      960

tcacgacagg aagaagagga gatctggcta cgattcatgg catgaatagg cctttcctcc     1020

tgcttatggc tacgccattg gagcgcgcgc aacatctcca gtccagccgc cacagacgag     1080

ctctggatac taactactgc ttctccagca ctgagaagaa ctgctgcgta agacagcttt     1140

acatcgactt ccgcaaggac ctgggttgga agtggataca cgagcccaag ggatatcatg     1200

ccaacttctg cctcgggccc tgtccctaca tctggtcatt ggatacacag tacagcaagg     1260

tactcgctct gtacaaccag cacaaccctg gtgcaagcgc agctccctgc tgtgttcccc     1320

aggctctgga accattgcct attgtttatt atgtaggacg aaaaccgaag gtcgagcagc     1380

tcagtaacat gatcgttcgg agctgcaagt gctctggctc aggcgagggc agaggcagcc     1440

tgctgacatg tggcgacgtg gaagagaacc ccgggcctag tccaggtcaa ggtacacaga     1500

gtgagaacag ttgcacacac tttcccggca acttgcctaa tatgctgagg gacctccggg     1560

atgctttctc tcgggtaaaa actttttttc aaatgaaaga ccaactcgat aacctccttc     1620

tgaaggagag cctcctggag gacttcaagg gatatttggg gtgccaagct ttgtccgaga     1680

tgattcagtt ctacttggaa gaggtgatgc cacaagcgga gaaccaagac ccggacatca     1740

aggctcacgt caatagcttg ggagaaaacc tgaagaccct gcggttgagg ctgcgccgct     1800

gtcataggtt ccttccatgt gagaacaaat ccaaagctgt ggaacaggtc aaaaatgctt     1860

tcaacaaact gcaggagaaa ggtatatata aggccatgtc tgaatttgac atatttatca     1920

actacataga ggcgtatatg accatgaaga ttcgcaat                             1958


<210>  14
<211>  4902
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Full coding sequence of the CAR construct comprising the 
       TNF-alpha scFv, IgG4 hinge, CD28 transmembrane domain, CD28 
       co-stimulatory domain, CD3 zeta signalling domain with a T2A skip
       peptide to FOXP3 in the same cassette and a NFAT inducible 
       

<400>  14
atggctttgc ctgtgactgc actgttgctt cccttggctc tgcttctcca tgctgctaga       60

ccggactata aagatgacga tgataagggc gggtccgagg tgcagctggt ggagtctggg      120

ggaggcttgg tacagcccgg caggtccctg agactctcct gtgcggcctc tggattcacc      180

tttgatgatt atgccatgca ctgggtccgg caagctccag ggaagggcct ggaatgggtc      240

tcagctatca cttggaatag tggtcacata gactatgcgg actctgtgga gggccgattc      300

accatctcca gagacaacgc caagaactcc ctgtatctgc aaatgaacag tctgagagct      360

gaggatacgg ccgtatatta ctgtgcgaaa gtctcgtacc ttagcaccgc gtcctccctt      420

gactattggg gccaaggtac cctggtcacc gtctcgagtg gtggtggtgg gtctggcgga      480

ggtggtagtg gaggtggtgg gtctgacatc cagatgaccc agtctccatc ctccctgtct      540

gcatctgtag gggacagagt caccatcact tgtcgggcaa gtcagggcat cagaaattac      600

ttagcctggt atcagcaaaa accagggaaa gcccctaagc tcctgatcta tgctgcatcc      660

actttgcaat caggggtccc atctcggttc agtggcagtg gatctgggac agatttcact      720

ctcaccatca gcagcctaca gcctgaagat gttgcaactt attactgtca aaggtataac      780

cgtgcaccgt atacttttgg ccagggcacc aaggtggaaa tcaaagctag cgcagaaagc      840

aagtatggtc ctccctgccc cccgtgccca ttttgggtgc tggtggtggt tgggggagtc      900

ctggcttgct atagcttgct agtaacagtg gcctttatta ttttctgggt gaggagtaag      960

aggagcaggc tcctgcacag tgactacatg aacatgactc caagacgcct aggtcccact     1020

cgcaagcatt accagcccta tgccccacca cgcgacttcg cagcctatcg ctccagagtg     1080

aagttcagca ggagcgcaga cgctccagct taccagcagg gccagaacca gctctataac     1140

gagctcaatc taggacgaag agaggagtac gatgttttgg acaagagacg tggccgggac     1200

cctgagatgg ggggaaagcc gagaaggaag aaccctcagg aaggcctgta caatgaactg     1260

cagaaagata agatggcgga ggcctacagt gagattggga tgaaaggcga gcgccggagg     1320

ggcaaggggc acgatggcct ttaccagggt ctcagtacag ccaccaagga cacctacgac     1380

gcccttcaca tgcaggccct gccccctcgc ggctcaggcg agggcagagg cagcctgctg     1440

acatgtggcg acgtggaaga gaaccccggg cctatgccta atcctcggcc tggaaagcct     1500

agcgctcctt ctcttgctct gggaccttct cctggcgcct ctccatcttg gagagccgct     1560

cctaaagcca gcgatctgct gggagctaga ggacctggcg gcacatttca gggcagagat     1620

cttagaggcg gagcccacgc tagctcctcc agccttaatc ctatgcctcc tagccagctc     1680

cagctgccta cactgcctct ggttatggtg gctcctagcg gagctagact gggccctctg     1740

cctcatctgc aagctctgct gcaggacaga ccccacttca tgcaccagct gagcaccgtg     1800

gatgcccacg caagaacacc tgtgctgcag gttcaccctc tggaatcccc agccatgatc     1860

agcctgacac ctccaacaac agccaccggc gtgttcagcc tgaaagccag acctggactg     1920

cctcctggca tcaatgtggc cagcctggaa tgggtgtcca gagaacctgc tctgctgtgc     1980

acattcccca atccaagcgc tcccagaaag gacagcacac tgtctgccgt gcctcagagc     2040

agctatcccc tgcttgctaa cggcgtgtgc aagtggcctg gatgcgagaa ggtgttcgag     2100

gaacccgagg acttcctgaa gcactgccag gccgatcatc tgctggacga gaaaggcaga     2160

gcccagtgtc tgctccagcg cgagatggtg cagtctctgg aacagcagct ggtcctggaa     2220

aaagaaaagc tgagcgccat gcaggcccac ctggccggaa aaatggccct gacaaaggcc     2280

agcagcgtgg cctcttctga taagggcagc tgctgcattg tggccgctgg atctcaggga     2340

cctgtggttc ctgcttggag cggacctaga gaggcccctg attctctgtt tgccgtgcgg     2400

agacacctgt ggggctctca cggcaactct actttccccg agttcctgca caacatggac     2460

tacttcaagt tccacaacat gcggcctcca ttcacctacg ccacactgat cagatgggcc     2520

attctggaag cccctgagaa gcagagaacc ctgaacgaga tctaccactg gtttacccgg     2580

atgttcgcct tcttccggaa tcaccctgcc acctggaaga acgccatccg gcacaatctg     2640

agcctgcaca agtgcttcgt gcgcgtggaa tctgagaaag gcgccgtgtg gacagtggac     2700

gagctggaat tcagaaagaa gagaagccag cggcctagcc ggtgcagcaa tcctacacct     2760

ggaccttaat agacgcgtgg gttaggggag gcgcttttcc caaggcagtc tggagcatgc     2820

gctaagcgat cgcgcccgct gggcacttgg cgctacacaa gtggcctctg gcctcgcaca     2880

cattccagga ggaaaaactg tttcatacag aaggcgtgga ggaaaaactg tttcatacag     2940

aaggcgtgga ggaaaaactg tttcatacag aaggcgtgga ggaaaaactg tttcatacag     3000

aaggcgtgga ggaaaaactg tttcatacag aaggcgtgga ggaaaaactg tttcatacag     3060

aaggcgtcag aattaacagt ataaattgca tctcttgttc aagagttccc tatcactcga     3120

gcggtcgcca ccatgccacc ttctggactg cggttgcttc cgttgctgtt gccactgctt     3180

tggctgcttg ttctgacacc tggcagaccc gcagccggtt tgtcaacatg caaaacgatc     3240

gacatggagc tggtaaagcg caagcgcatt gaggcaatca gagggcagat cttgagcaag     3300

cttcggctcg cctctcctcc aagccagggc gaggtgccac ccggtccgct gccggaagcg     3360

gttctcgctc tctataacag cactagagat agggtcgcag gtgagtctgc tgaacctgaa     3420

cctgaaccgg aagctgacta ttacgctaaa gaggtgacga gagttctcat ggtggaaact     3480

cacaatgaga tttatgataa atttaaacag tctacccaca gcatttatat gttttttaac     3540

accagtgagc tccgcgaggc tgtccctgaa cctgtcctcc tttccagggc agaattgcgg     3600

cttctgaggc tgaagcttaa agtagagcaa cacgtggagc tctaccagaa atatagtaat     3660

aacagctgga gatatctgtc aaaccgactg ctggcgccct ccgacagtcc agagtggctt     3720

tcctttgacg ttactggcgt ggtgcggcaa tggctttcaa gaggcgggga aatcgagggc     3780

ttcaggctta gcgctcactg ctcatgtgat agtagggata acacacttca ggtagacatt     3840

aatgggttca cgacaggaag aagaggagat ctggctacga ttcatggcat gaataggcct     3900

ttcctcctgc ttatggctac gccattggag cgcgcgcaac atctccagtc cagccgccac     3960

agacgagctc tggatactaa ctactgcttc tccagcactg agaagaactg ctgcgtaaga     4020

cagctttaca tcgacttccg caaggacctg ggttggaagt ggatacacga gcccaaggga     4080

tatcatgcca acttctgcct cgggccctgt ccctacatct ggtcattgga tacacagtac     4140

agcaaggtac tcgctctgta caaccagcac aaccctggtg caagcgcagc tccctgctgt     4200

gttccccagg ctctggaacc attgcctatt gtttattatg taggacgaaa accgaaggtc     4260

gagcagctca gtaacatgat cgttcggagc tgcaagtgct ctggctcagg cgagggcaga     4320

ggcagcctgc tgacatgtgg cgacgtggaa gagaaccccg ggcctatgca cagctcagca     4380

ctgctctgtt gcctggtcct cctgactggg gtgagggcca gtccaggtca aggtacacag     4440

agtgagaaca gttgcacaca ctttcccggc aacttgccta atatgctgag ggacctccgg     4500

gatgctttct ctcgggtaaa aacttttttt caaatgaaag accaactcga taacctcctt     4560

ctgaaggaga gcctcctgga ggacttcaag ggatatttgg ggtgccaagc tttgtccgag     4620

atgattcagt tctacttgga agaggtgatg ccacaagcgg agaaccaaga cccggacatc     4680

aaggctcacg tcaatagctt gggagaaaac ctgaagaccc tgcggttgag gctgcgccgc     4740

tgtcataggt tccttccatg tgagaacaaa tccaaagctg tggaacaggt caaaaatgct     4800

ttcaacaaac tgcaggagaa aggtatatat aaggccatgt ctgaatttga catatttatc     4860

aactacatag aggcgtatat gaccatgaag attcgcaatt ga                        4902


<210>  15
<211>  4815
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Full sequence of a CAR construct comprising of IFN-gamma scFv TII
       2G1G7, an IgG4 hinge, CD28 transmembrane domain, CD28 
       co-stimulatory domain, CD3 zeta signalling domain with a T2A skip
       peptide to FOXP3 in the same cassette and a NFAT inducible 
       

<400>  15
atggctttgc ctgtgactgc actgttgctt cccttggctc tgcttctcca tgctgctaga       60

ccgcaagtta agctggagca gtcaggacct ggcctggtgg cgccctcaca gagcctgtcc      120

atcacttgca ctgtctctgg gttttcatta accagctatg gtgtacactg ggttcgccag      180

tctccaggaa agggtctgga gtggctggga gtaatatggg ctggtggaag cacaaattat      240

aattcggctc tcatgtccag actgagcatc agtaaagaca actccaagag ccaagttttc      300

ttaaaaatga acagtctgca aactgatgac acagccatgt actactgtgc cagaagagat      360

ggtaacaggt actatactat ggactactgg ggtcaaggag cttcagtcac cgtctcctca      420

ggtggtggtg ggtctggcgg aggtggtagt ggaggtggtg ggtctgaaaa tgtgctcacc      480

cagtctccag caatcatgtc tgcatctcca ggggaaaagg tcaccatgac ctgcagggcc      540

agctcaagtg taagttccag ttacttgcac tggtaccagc agaagtcagg tggctccccc      600

aaactctgga tttatagaac atccaacttg gcttctggag tccctgctcg cttcagtggc      660

agtgggtctg ggacctctta ctctctcaca atcagcagtg tggaggctga agatgctgcc      720

acttattact gccagcagta cagtggttac ccgctcacgt tcggtgctgg gaccaagctg      780

gagctgaaac gggctagcgc agaaagcaag tatggtcctc cctgcccccc gtgcccattt      840

tgggtgctgg tggtggttgg gggagtcctg gcttgctata gcttgctagt aacagtggcc      900

tttattattt tctgggtgag gagtaagagg agcaggctcc tgcacagtga ctacatgaac      960

atgactccaa gacgcctagg tcccactcgc aagcattacc agccctatgc cccaccacgc     1020

gacttcgcag cctatcgctc cagagtgaag ttcagcagga gcgcagacgc tccagcttac     1080

cagcagggcc agaaccagct ctataacgag ctcaatctag gacgaagaga ggagtacgat     1140

gttttggaca agagacgtgg ccgggaccct gagatggggg gaaagccgag aaggaagaac     1200

cctcaggaag gcctgtacaa tgaactgcag aaagataaga tggcggaggc ctacagtgag     1260

attgggatga aaggcgagcg ccggaggggc aaggggcacg atggccttta ccagggtctc     1320

agtacagcca ccaaggacac ctacgacgcc cttcacatgc aggccctgcc ccctcgcggc     1380

tcaggcgagg gcagaggcag cctgctgaca tgtggcgacg tggaagagaa ccccgggcct     1440

atgcctaatc ctcggcctgg aaagcctagc gctccttctc ttgctctggg accttctcct     1500

ggcgcctctc catcttggag agccgctcct aaagccagcg atctgctggg agctagagga     1560

cctggcggca catttcaggg cagagatctt agaggcggag cccacgctag ctcctccagc     1620

cttaatccta tgcctcctag ccagctccag ctgcctacac tgcctctggt tatggtggct     1680

cctagcggag ctagactggg ccctctgcct catctgcaag ctctgctgca ggacagaccc     1740

cacttcatgc accagctgag caccgtggat gcccacgcaa gaacacctgt gctgcaggtt     1800

caccctctgg aatccccagc catgatcagc ctgacacctc caacaacagc caccggcgtg     1860

ttcagcctga aagccagacc tggactgcct cctggcatca atgtggccag cctggaatgg     1920

gtgtccagag aacctgctct gctgtgcaca ttccccaatc caagcgctcc cagaaaggac     1980

agcacactgt ctgccgtgcc tcagagcagc tatcccctgc ttgctaacgg cgtgtgcaag     2040

tggcctggat gcgagaaggt gttcgaggaa cccgaggact tcctgaagca ctgccaggcc     2100

gatcatctgc tggacgagaa aggcagagcc cagtgtctgc tccagcgcga gatggtgcag     2160

tctctggaac agcagctggt cctggaaaaa gaaaagctga gcgccatgca ggcccacctg     2220

gccggaaaaa tggccctgac aaaggccagc agcgtggcct cttctgataa gggcagctgc     2280

tgcattgtgg ccgctggatc tcagggacct gtggttcctg cttggagcgg acctagagag     2340

gcccctgatt ctctgtttgc cgtgcggaga cacctgtggg gctctcacgg caactctact     2400

ttccccgagt tcctgcacaa catggactac ttcaagttcc acaacatgcg gcctccattc     2460

acctacgcca cactgatcag atgggccatt ctggaagccc ctgagaagca gagaaccctg     2520

aacgagatct accactggtt tacccggatg ttcgccttct tccggaatca ccctgccacc     2580

tggaagaacg ccatccggca caatctgagc ctgcacaagt gcttcgtgcg cgtggaatct     2640

gagaaaggcg ccgtgtggac agtggacgag ctggaattca gaaagaagag aagccagcgg     2700

cctagccggt gcagcaatcc tacacctgga ccttaataga cgcgtgggtt aggggaggcg     2760

cttttcccaa ggcagtctgg agcatgcgct aattagctag ccccgctggg cacttggcgc     2820

tacacaagtg gcctctggcc tcgcacacat tccaggagga aaaactgttt catacagaag     2880

gcgtggagga aaaactgttt catacagaag gcgtggagga aaaactgttt catacagaag     2940

gcgtggagga aaaactgttt catacagaag gcgtggagga aaaactgttt catacagaag     3000

gcgtggagga aaaactgttt catacagaag gcgtcagaat taacagtata aattgcatct     3060

cttgttcaag agttccctat cactcgagcg gtcgccacca tgccaccttc tggactgcgg     3120

ttgcttccgt tgctgttgcc actgctttgg ctgcttgttc tgacacctgg cagacccgca     3180

gccggtttgt caacatgcaa aacgatcgac atggagctgg taaagcgcaa gcgcattgag     3240

gcaatcagag ggcagatctt gagcaagctt cggctcgcct ctcctccaag ccagggcgag     3300

gtgccacccg gtccgctgcc ggaagcggtt ctcgctctct ataacagcac tagagatagg     3360

gtcgcaggtg agtctgctga acctgaacct gaaccggaag ctgactatta cgctaaagag     3420

gtgacgagag ttctcatggt ggaaactcac aatgagattt atgataaatt taaacagtct     3480

acccacagca tttatatgtt ttttaacacc agtgagctcc gcgaggctgt ccctgaacct     3540

gtcctccttt ccagggcaga attgcggctt ctgaggctga agcttaaagt agagcaacac     3600

gtggagctct accagaaata tagtaataac agctggagat atctgtcaaa ccgactgctg     3660

gcgccctccg acagtccaga gtggctttcc tttgacgtta ctggcgtggt gcggcaatgg     3720

ctttcaagag gcggggaaat cgagggcttc aggcttagcg ctcactgctc atgtgatagt     3780

agggataaca cacttcaggt agacattaat gggttcacga caggaagaag aggagatctg     3840

gctacgattc atggcatgaa taggcctttc ctcctgctta tggctacgcc attggagcgc     3900

gcgcaacatc tccagtccag ccgccacaga cgagctctgg atactaacta ctgcttctcc     3960

agcactgaga agaactgctg cgtaagacag ctttacatcg acttccgcaa ggacctgggt     4020

tggaagtgga tacacgagcc caagggatat catgccaact tctgcctcgg gccctgtccc     4080

tacatctggt cattggatac acagtacagc aaggtactcg ctctgtacaa ccagcacaac     4140

cctggtgcaa gcgcagctcc ctgctgtgtt ccccaggctc tggaaccatt gcctattgtt     4200

tattatgtag gacgaaaacc gaaggtcgag cagctcagta acatgatcgt tcggagctgc     4260

aagtgctctg gctcaggcga gggcagaggc agcctgctga catgtggcga cgtggaagag     4320

aaccccgggc ctagtccagg tcaaggtaca cagagtgaga acagttgcac acactttccc     4380

ggcaacttgc ctaatatgct gagggacctc cgggatgctt tctctcgggt aaaaactttt     4440

tttcaaatga aagaccaact cgataacctc cttctgaagg agagcctcct ggaggacttc     4500

aagggatatt tggggtgcca agctttgtcc gagatgattc agttctactt ggaagaggtg     4560

atgccacaag cggagaacca agacccggac atcaaggctc acgtcaatag cttgggagaa     4620

aacctgaaga ccctgcggtt gaggctgcgc cgctgtcata ggttccttcc atgtgagaac     4680

aaatccaaag ctgtggaaca ggtcaaaaat gctttcaaca aactgcagga gaaaggtata     4740

tataaggcca tgtctgaatt tgacatattt atcaactaca tagaggcgta tatgaccatg     4800

aagattcgca attga                                                      4815


<210>  16
<211>  160
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of IL-10

<400>  16

Ser Pro Gly Gln Gly Thr Gln Ser Glu Asn Ser Cys Thr His Phe Pro 
1               5                   10                  15      


Gly Asn Leu Pro Asn Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg 
            20                  25                  30          


Val Lys Thr Phe Phe Gln Met Lys Asp Gln Leu Asp Asn Leu Leu Leu 
        35                  40                  45              


Lys Glu Ser Leu Leu Glu Asp Phe Lys Gly Tyr Leu Gly Cys Gln Ala 
    50                  55                  60                  


Leu Ser Glu Met Ile Gln Phe Tyr Leu Glu Glu Val Met Pro Gln Ala 
65                  70                  75                  80  


Glu Asn Gln Asp Pro Asp Ile Lys Ala His Val Asn Ser Leu Gly Glu 
                85                  90                  95      


Asn Leu Lys Thr Leu Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu 
            100                 105                 110         


Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Asn Ala Phe 
        115                 120                 125             


Asn Lys Leu Gln Glu Lys Gly Ile Tyr Lys Ala Met Ser Glu Phe Asp 
    130                 135                 140                 


Ile Phe Ile Asn Tyr Ile Glu Ala Tyr Met Thr Met Lys Ile Arg Asn 
145                 150                 155                 160 


<210>  17
<211>  389
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of TGF-beta

<400>  17

Pro Pro Ser Gly Leu Arg Leu Leu Pro Leu Leu Leu Pro Leu Leu Trp 
1               5                   10                  15      


Leu Leu Val Leu Thr Pro Gly Arg Pro Ala Ala Gly Leu Ser Thr Cys 
            20                  25                  30          


Lys Thr Ile Asp Met Glu Leu Val Lys Arg Lys Arg Ile Glu Ala Ile 
        35                  40                  45              


Arg Gly Gln Ile Leu Ser Lys Leu Arg Leu Ala Ser Pro Pro Ser Gln 
    50                  55                  60                  


Gly Glu Val Pro Pro Gly Pro Leu Pro Glu Ala Val Leu Ala Leu Tyr 
65                  70                  75                  80  


Asn Ser Thr Arg Asp Arg Val Ala Gly Glu Ser Ala Glu Pro Glu Pro 
                85                  90                  95      


Glu Pro Glu Ala Asp Tyr Tyr Ala Lys Glu Val Thr Arg Val Leu Met 
            100                 105                 110         


Val Glu Thr His Asn Glu Ile Tyr Asp Lys Phe Lys Gln Ser Thr His 
        115                 120                 125             


Ser Ile Tyr Met Phe Phe Asn Thr Ser Glu Leu Arg Glu Ala Val Pro 
    130                 135                 140                 


Glu Pro Val Leu Leu Ser Arg Ala Glu Leu Arg Leu Leu Arg Leu Lys 
145                 150                 155                 160 


Leu Lys Val Glu Gln His Val Glu Leu Tyr Gln Lys Tyr Ser Asn Asn 
                165                 170                 175     


Ser Trp Arg Tyr Leu Ser Asn Arg Leu Leu Ala Pro Ser Asp Ser Pro 
            180                 185                 190         


Glu Trp Leu Ser Phe Asp Val Thr Gly Val Val Arg Gln Trp Leu Ser 
        195                 200                 205             


Arg Gly Gly Glu Ile Glu Gly Phe Arg Leu Ser Ala His Cys Ser Cys 
    210                 215                 220                 


Asp Ser Arg Asp Asn Thr Leu Gln Val Asp Ile Asn Gly Phe Thr Thr 
225                 230                 235                 240 


Gly Arg Arg Gly Asp Leu Ala Thr Ile His Gly Met Asn Arg Pro Phe 
                245                 250                 255     


Leu Leu Leu Met Ala Thr Pro Leu Glu Arg Ala Gln His Leu Gln Ser 
            260                 265                 270         


Ser Arg His Arg Arg Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser Thr 
        275                 280                 285             


Glu Lys Asn Cys Cys Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp 
    290                 295                 300                 


Leu Gly Trp Lys Trp Ile His Glu Pro Lys Gly Tyr His Ala Asn Phe 
305                 310                 315                 320 


Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr Ser 
                325                 330                 335     


Lys Val Leu Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala Ala 
            340                 345                 350         


Pro Cys Cys Val Pro Gln Ala Leu Glu Pro Leu Pro Ile Val Tyr Tyr 
        355                 360                 365             


Val Gly Arg Lys Pro Lys Val Glu Gln Leu Ser Asn Met Ile Val Arg 
    370                 375                 380                 


Ser Cys Lys Cys Ser 
385                 


<210>  18
<211>  431
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of FOXP3

<400>  18

Met Pro Asn Pro Arg Pro Gly Lys Pro Ser Ala Pro Ser Leu Ala Leu 
1               5                   10                  15      


Gly Pro Ser Pro Gly Ala Ser Pro Ser Trp Arg Ala Ala Pro Lys Ala 
            20                  25                  30          


Ser Asp Leu Leu Gly Ala Arg Gly Pro Gly Gly Thr Phe Gln Gly Arg 
        35                  40                  45              


Asp Leu Arg Gly Gly Ala His Ala Ser Ser Ser Ser Leu Asn Pro Met 
    50                  55                  60                  


Pro Pro Ser Gln Leu Gln Leu Pro Thr Leu Pro Leu Val Met Val Ala 
65                  70                  75                  80  


Pro Ser Gly Ala Arg Leu Gly Pro Leu Pro His Leu Gln Ala Leu Leu 
                85                  90                  95      


Gln Asp Arg Pro His Phe Met His Gln Leu Ser Thr Val Asp Ala His 
            100                 105                 110         


Ala Arg Thr Pro Val Leu Gln Val His Pro Leu Glu Ser Pro Ala Met 
        115                 120                 125             


Ile Ser Leu Thr Pro Pro Thr Thr Ala Thr Gly Val Phe Ser Leu Lys 
    130                 135                 140                 


Ala Arg Pro Gly Leu Pro Pro Gly Ile Asn Val Ala Ser Leu Glu Trp 
145                 150                 155                 160 


Val Ser Arg Glu Pro Ala Leu Leu Cys Thr Phe Pro Asn Pro Ser Ala 
                165                 170                 175     


Pro Arg Lys Asp Ser Thr Leu Ser Ala Val Pro Gln Ser Ser Tyr Pro 
            180                 185                 190         


Leu Leu Ala Asn Gly Val Cys Lys Trp Pro Gly Cys Glu Lys Val Phe 
        195                 200                 205             


Glu Glu Pro Glu Asp Phe Leu Lys His Cys Gln Ala Asp His Leu Leu 
    210                 215                 220                 


Asp Glu Lys Gly Arg Ala Gln Cys Leu Leu Gln Arg Glu Met Val Gln 
225                 230                 235                 240 


Ser Leu Glu Gln Gln Leu Val Leu Glu Lys Glu Lys Leu Ser Ala Met 
                245                 250                 255     


Gln Ala His Leu Ala Gly Lys Met Ala Leu Thr Lys Ala Ser Ser Val 
            260                 265                 270         


Ala Ser Ser Asp Lys Gly Ser Cys Cys Ile Val Ala Ala Gly Ser Gln 
        275                 280                 285             


Gly Pro Val Val Pro Ala Trp Ser Gly Pro Arg Glu Ala Pro Asp Ser 
    290                 295                 300                 


Leu Phe Ala Val Arg Arg His Leu Trp Gly Ser His Gly Asn Ser Thr 
305                 310                 315                 320 


Phe Pro Glu Phe Leu His Asn Met Asp Tyr Phe Lys Phe His Asn Met 
                325                 330                 335     


Arg Pro Pro Phe Thr Tyr Ala Thr Leu Ile Arg Trp Ala Ile Leu Glu 
            340                 345                 350         


Ala Pro Glu Lys Gln Arg Thr Leu Asn Glu Ile Tyr His Trp Phe Thr 
        355                 360                 365             


Arg Met Phe Ala Phe Phe Arg Asn His Pro Ala Thr Trp Lys Asn Ala 
    370                 375                 380                 


Ile Arg His Asn Leu Ser Leu His Lys Cys Phe Val Arg Val Glu Ser 
385                 390                 395                 400 


Glu Lys Gly Ala Val Trp Thr Val Asp Glu Leu Glu Phe Arg Lys Lys 
                405                 410                 415     


Arg Ser Gln Arg Pro Ser Arg Cys Ser Asn Pro Thr Pro Gly Pro 
            420                 425                 430     


<210>  19
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 VH

<400>  19

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Ser Ser Thr Gly Ala Ser Thr Thr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Gly Gly Ala Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  20
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 VL

<400>  20

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Asn Ala Pro Thr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  21
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 & Anti-IFNy NovImmune Clone A6 - 
       Emapalumab - CDRH1 (Kabat)

<400>  21

Ser Tyr Ala Met Ser 
1               5   


<210>  22
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 & Anti-IFNy NovImmune Clone A6 - 
       Emapalumab - CDRH1 (AbM)

<400>  22

Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser 
1               5                   10  


<210>  23
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2  & Anti-IFNy NovImmune Clone A6 - 
       Emapalumab - CDRH1 (IMGT)

<400>  23

Gly Phe Thr Phe Ser Ser Tyr Ala 
1               5               


<210>  24
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRH2 (Kabat)

<400>  24

Ser Ile Ser Ser Thr Gly Ala Ser Thr Thr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  25
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRH2 (AbM)

<400>  25

Ser Ile Ser Ser Thr Gly Ala Ser Thr Thr 
1               5                   10  


<210>  26
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRH2 (IMGT)

<400>  26

Ile Ser Ser Thr Gly Ala Ser Thr 
1               5               


<210>  27
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRH3 (Kabat, AbM)

<400>  27

Gly Gly Ala Ala Phe Asp Tyr 
1               5           


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRH3 (IMGT)

<400>  28

Ala Lys Gly Gly Ala Ala Phe Asp Tyr 
1               5                   


<210>  29
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRL1 (Kabat, AbM)

<400>  29

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 
1               5                   10      


<210>  30
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRL1 (IMGT)

<400>  30

Gln Ser Ile Ser Ser Tyr 
1               5       


<210>  31
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRL2 (Kabat, AbM)

<400>  31

Ser Ala Ser Tyr Leu Gln Ser 
1               5           


<210>  32
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFvclone P3H2 - CDRL2 (IMGT)

<400>  32

Ser Ala 
1       


<210>  33
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-TNF-alpha scFv clone P3H2 - CDRL3 (Kabat, AbM, IMGT)

<400>  33

Gln Gln Ala Asn Asn Ala Pro Thr Thr 
1               5                   


<210>  34
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 VH

<400>  34

Glu Val Lys Leu Glu Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Met His Trp Ile Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Ala Ile Tyr Pro Gly Ile Ser Asp Thr Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Val Lys Ala Lys Leu Thr Ala Val Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Asp Glu Asp Phe Asp Gly Phe Ala Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210>  35
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 VL

<400>  35

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Arg Gly 
                85                  90                  95      


Ser His Ala Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Arg 
    


<210>  36
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRH1 (Kabat)

<400>  36

Asn Tyr Trp Met His 
1               5   


<210>  37
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRH1 (AbM)

<400>  37

Gly Tyr Thr Phe Thr Asn Tyr Trp Met His 
1               5                   10  


<210>  38
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRH1 (IMGT)

<400>  38

Gly Tyr Thr Phe Thr Asn Tyr Trp 
1               5               


<210>  39
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRH2 (Kabat)

<400>  39

Ala Ile Tyr Pro Gly Ile Ser Asp Thr Ser Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Val 
    


<210>  40
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRH2 (AbM)

<400>  40

Ala Ile Tyr Pro Gly Ile Ser Asp Thr Ser 
1               5                   10  


<210>  41
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRH2 (IMGT)

<400>  41

Ile Tyr Pro Gly Ile Ser Asp Thr 
1               5               


<210>  42
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRH3 (Kabat, AbM)

<400>  42

Asp Glu Asp Phe Asp Gly Phe Ala Tyr 
1               5                   


<210>  43
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRH3 (IMGT)

<400>  43

Thr Arg Asp Glu Asp Phe Asp Gly Phe Ala Tyr 
1               5                   10      


<210>  44
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRL1 (Kabat, AbM)

<400>  44

Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Asp 
1               5                   10                  15      


<210>  45
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRL1 (IMGT)

<400>  45

Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  46
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRL2 (Kabat, AbM)

<400>  46

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  47
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 & Anti-IL17A Clone Mab126 - Ixekizumab -
       CDRL2 (IMGT)

<400>  47

Lys Val 
1       


<210>  48
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 6AE52 - CDRL3 (Kabat, AbM, IMGT)

<400>  48

Phe Arg Gly Ser His Ala Pro Tyr Thr 
1               5                   


<210>  49
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 VH

<400>  49

Gln Val Lys Leu Glu Gln Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Arg Asp Gly Asn Arg Tyr Tyr Thr Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Ala Ser Val Thr Val Ser Ser 
        115                 


<210>  50
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 VL

<400>  50

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Gly Ser Pro Lys Leu Trp 
        35                  40                  45              


Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu 
65                  70                  75                  80  


Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Gly Tyr Pro 
                85                  90                  95      


Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg 
            100                 105                 


<210>  51
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRH1 (Kabat)

<400>  51

Ser Tyr Gly Val His 
1               5   


<210>  52
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRH1 (AbM)

<400>  52

Gly Phe Ser Leu Thr Ser Tyr Gly Val His 
1               5                   10  


<210>  53
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRH1 (IMGT)

<400>  53

Gly Phe Ser Leu Thr Ser Tyr Gly 
1               5               


<210>  54
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRH2 (Kabat)

<400>  54

Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met Ser 
1               5                   10                  15      


<210>  55
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRH2 (AbM)

<400>  55

Val Ile Trp Ala Gly Gly Ser Thr Asn 
1               5                   


<210>  56
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRH2 (IMGT)

<400>  56

Ile Trp Ala Gly Gly Ser Thr 
1               5           


<210>  57
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRH3 (Kabat, AbM)

<400>  57

Arg Asp Gly Asn Arg Tyr Tyr Thr Met Asp Tyr 
1               5                   10      


<210>  58
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRH3 (IMGT)

<400>  58

Ala Arg Arg Asp Gly Asn Arg Tyr Tyr Thr Met Asp Tyr 
1               5                   10              


<210>  59
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRL1 (Kabat, AbM)

<400>  59

Arg Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His 
1               5                   10          


<210>  60
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRL1 (IMGT)

<400>  60

Ser Ser Val Ser Ser Ser Tyr 
1               5           


<210>  61
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRL2 (Kabat, AbM)

<400>  61

Arg Thr Ser Asn Leu Ala Ser 
1               5           


<210>  62
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRL2 (IMGT)

<400>  62

Arg Thr 
1       


<210>  63
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IFN-gamma scFv TII 2G1G7 - CDRL3 (Kabat, AbM, IMGT)

<400>  63

Gln Gln Tyr Ser Gly Tyr Pro Leu Thr 
1               5                   


<210>  64
<211>  243
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of anti-TNFa scFv clone 2DE7

<400>  64

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val 
    50                  55                  60                  


Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 
        115                 120                 125             


Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro 
    130                 135                 140                 


Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 
145                 150                 155                 160 


Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro 
                165                 170                 175     


Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser 
            180                 185                 190         


Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
        195                 200                 205             


Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys 
    210                 215                 220                 


Gln Arg Tyr Asn Arg Ala Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val 
225                 230                 235                 240 


Glu Ile Lys 
            


<210>  65
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7 VH

<400>  65

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val 
    50                  55                  60                  


Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  66
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7 VL

<400>  66

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Arg Tyr Asn Arg Ala Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  67
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7  & Anti-TNFa scFv clone 2SD4- 
       CDRH1 (Kabat)

<400>  67

Asp Tyr Ala Met His 
1               5   


<210>  68
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7  & Anti-TNFa scFv clone 2SD4- 
       CDRH1 (AbM)

<400>  68

Gly Phe Thr Phe Asp Asp Tyr Ala Met His 
1               5                   10  


<210>  69
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7 & Anti-TNFa scFv clone 2SD4 - 
       CDRH1 (IMGT)

<400>  69

Gly Phe Thr Phe Asp Asp Tyr Ala 
1               5               


<210>  70
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7  & Anti-TNFa scFv clone 2SD4- 
       CDRH2 (Kabat)

<400>  70

Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val Glu 
1               5                   10                  15      


Gly 
    


<210>  71
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7 & Anti-TNFa scFv clone 2SD4 - 
       CDRH2 (AbM)

<400>  71

Ala Ile Thr Trp Asn Ser Gly His Ile Asp 
1               5                   10  


<210>  72
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7  & Anti-TNFa scFv clone 2SD4 - 
       CDRH2 (IMGT)

<400>  72

Ile Thr Trp Asn Ser Gly His Ile 
1               5               


<210>  73
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7  - CDRH3 (Kabat, AbM)

<400>  73

Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr 
1               5                   10          


<210>  74
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7  - CDRH3 (IMGT)

<400>  74

Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr 
1               5                   10                  


<210>  75
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7 & Anti-TNFa scFv clone 2SD4 - 
       CDRL1 (Kabat, AbM)

<400>  75

Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala 
1               5                   10      


<210>  76
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7 & Anti-TNFa scFv clone 2SD4 - 
       CDRL1 (IMGT)

<400>  76

Gln Gly Ile Arg Asn Tyr 
1               5       


<210>  77
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7 & Anti-TNFa scFv clone 2SD4 - 
       CDRL2 (Kabat, AbM)

<400>  77

Ala Ala Ser Thr Leu Gln Ser 
1               5           


<210>  78
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7 & Anti-TNFa scFv clone 2SD4 - 
       CDRL2 (IMGT)

<400>  78

Ala Ala 
1       


<210>  79
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone Humira D2E7  - CDRL3 (Kabat, AbM, IMGT)

<400>  79

Gln Arg Tyr Asn Arg Ala Pro Tyr Thr 
1               5                   


<210>  80
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone 2SD4 VH

<400>  80

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val 
        35                  40                  45              


Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val 
    50                  55                  60                  


Glu Gly Arg Phe Ala Val Ser Arg Asp Asn Ala Lys Asn Ala Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Lys Ala Ser Tyr Leu Ser Thr Ser Ser Leu Asp Asn Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  81
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone 2SD4 VL

<400>  81

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Val Arg Ala Ser Gln Gly Ile Arg Asn Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Tyr 
                85                  90                  95      


Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  82
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone 2SD4 VL - CDRH3 (Kabat, AbM)

<400>  82

Ala Ser Tyr Leu Ser Thr Ser Ser Leu Asp Asn 
1               5                   10      


<210>  83
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone 2SD4 VL - CDRH3 (IMGT)

<400>  83

Thr Lys Ala Ser Tyr Leu Ser Thr Ser Ser Leu Asp Asn 
1               5                   10              


<210>  84
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone 2SD4 VL - CDRL3 (Kabat, AbM, IMGT)

<400>  84

Gln Lys Tyr Asn Ser Ala Pro Tyr Ala 
1               5                   


<210>  85
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab VH

<400>  85

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Ile Phe Ser Asn His 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Glu Ile Arg Ser Lys Ser Ile Asn Ser Ala Thr His Tyr Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ala 
65                  70                  75                  80  


Val Tyr Leu Gln Met Thr Asp Leu Arg Thr Glu Asp Thr Gly Val Tyr 
                85                  90                  95      


Tyr Cys Ser Arg Asn Tyr Tyr Gly Ser Thr Tyr Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Leu Thr Val Ser 
        115                 


<210>  86
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab VL

<400>  86

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Phe Val Gly Ser Ser 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Glu Ser Met Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Thr Val Glu Ser 
65                  70                  75                  80  


Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser His Ser Trp Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Asn Leu Glu Val Lys 
            100                 105         


<210>  87
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRH1 (Kabat)

<400>  87

Asn His Trp Met Asn 
1               5   


<210>  88
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRH1 (AbM)

<400>  88

Gly Phe Ile Phe Ser Asn His Trp Met Asn 
1               5                   10  


<210>  89
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRH1 (IMGT)

<400>  89

Gly Phe Ile Phe Ser Asn His Trp 
1               5               


<210>  90
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRH2 (Kabat)

<400>  90

Glu Ile Arg Ser Lys Ser Ile Asn Ser Ala Thr His Tyr Ala Glu Ser 
1               5                   10                  15      


Val Lys Gly 
            


<210>  91
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRH2 (AbM)

<400>  91

Glu Ile Arg Ser Lys Ser Ile Asn Ser Ala Thr His 
1               5                   10          


<210>  92
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRH2 (IMGT)

<400>  92

Ile Arg Ser Lys Ser Ile Asn Ser Ala Thr 
1               5                   10  


<210>  93
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRH3 (Kabat, AbM)

<400>  93

Asn Tyr Tyr Gly Ser Thr Tyr Asp Tyr 
1               5                   


<210>  94
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRH3 (IMGT)

<400>  94

Ser Arg Asn Tyr Tyr Gly Ser Thr Tyr Asp Tyr 
1               5                   10      


<210>  95
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRL1 (Kabat, AbM)

<400>  95

Arg Ala Ser Gln Phe Val Gly Ser Ser Ile His 
1               5                   10      


<210>  96
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRL1 (IMGT)

<400>  96

Gln Phe Val Gly Ser Ser 
1               5       


<210>  97
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRL2 (Kabat, AbM)

<400>  97

Tyr Ala Ser Glu Ser Met Ser 
1               5           


<210>  98
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRL2 (IMGT)

<400>  98

Tyr Ala 
1       


<210>  99
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone cA2 - Infliximab  - CDRL3 (Kabat, AbM, IMGT)

<400>  99

Gln Gln Ser His Ser Trp Pro Phe Thr 
1               5                   


<210>  100
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab VH

<400>  100

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Gly Ser Ser Gly Trp Tyr Val Pro His Trp Phe Asp Pro 
            100                 105                 110         


Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser 
        115                 120             


<210>  101
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab VL

<400>  101

Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 
1               5                   10                  15      


Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Val Ser Asn 
            20                  25                  30          


Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val 
        35                  40                  45              


Ile Tyr Glu Asp Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Ile Asp Ser Ser Ser Asn Thr Ala Ser Leu Thr Ile Ser Gly 
65                  70                  75                  80  


Leu Glu Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Gly 
                85                  90                  95      


Ser Asn Arg Trp Met Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 
            100                 105                 110         


<210>  102
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRH2 (Kabat)

<400>  102

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  103
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRH2 (AbM)

<400>  103

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr 
1               5                   10  


<210>  104
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRH2 (IMGT)

<400>  104

Ile Ser Gly Ser Gly Gly Ser Thr 
1               5               


<210>  105
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRH3 (Kabat, AbM)

<400>  105

Asp Gly Ser Ser Gly Trp Tyr Val Pro His Trp Phe Asp Pro 
1               5                   10                  


<210>  106
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRH3 (IMGT)

<400>  106

Ala Lys Asp Gly Ser Ser Gly Trp Tyr Val Pro His Trp Phe Asp Pro 
1               5                   10                  15      


<210>  107
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRL1 (Kabat, AbM)

<400>  107

Thr Arg Ser Ser Gly Ser Ile Val Ser Asn Tyr Val Gln 
1               5                   10              


<210>  108
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRL1 (IMGT)

<400>  108

Ser Gly Ser Ile Val Ser Asn Tyr 
1               5               


<210>  109
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRL2 (Kabat, AbM)

<400>  109

Glu Asp Asn Arg Arg Pro Ser 
1               5           


<210>  110
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRL2 (IMGT)

<400>  110

Glu Asp 
1       


<210>  111
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy NovImmune Clone A6 - Emapalumab  - CDRL3 (Kabat, AbM, 
       IMGT)

<400>  111

Gln Ser Tyr Asp Gly Ser Asn Arg Trp Met 
1               5                   10  


<210>  112
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab VH

<400>  112

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Leu Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Ser 
            20                  25                  30          


Trp Ile Asn Trp Val Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly 
        35                  40                  45              


Arg Ile Asp Pro Ser Asp Gly Glu Val His Tyr Asn Gln Asp Phe Lys 
    50                  55                  60                  


Asp Lys Ala Thr Leu Thr Thr Val Asp Lys Ser Thr Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Phe Leu Pro Trp Phe Ala Asp Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  113
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab VL

<400>  113

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn Val Asp Thr Tyr 
            20                  25                  30          


Val Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Asp Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Ser Tyr Asn Tyr Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Val Lys Arg 
            100                 105             


<210>  114
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRH1 (Kabat)

<400>  114

Ser Ser Trp Ile Asn 
1               5   


<210>  115
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRH1 (AbM)

<400>  115

Gly Tyr Ile Phe Thr Ser Ser Trp Ile Asn 
1               5                   10  


<210>  116
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRH1 (IMGT)

<400>  116

Gly Tyr Ile Phe Thr Ser Ser Trp 
1               5               


<210>  117
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRH2 (Kabat)

<400>  117

Arg Ile Asp Pro Ser Asp Gly Glu Val His Tyr Asn Gln Asp Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  118
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRH2 (AbM)

<400>  118

Ile Asp Pro Ser Asp Gly Glu Val 
1               5               


<210>  119
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRH2 (IMGT)

<400>  119

Arg Ile Asp Pro Ser Asp Gly Glu Val His 
1               5                   10  


<210>  120
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRH3 (Kabat, AbM)

<400>  120

Gly Phe Leu Pro Trp Phe Ala Asp 
1               5               


<210>  121
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRH3 (IMGT)

<400>  121

Ala Arg Gly Phe Leu Pro Trp Phe Ala Asp 
1               5                   10  


<210>  122
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRL1 (Kabat, AbM)

<400>  122

Lys Ala Ser Glu Asn Val Asp Thr Tyr Val Ser 
1               5                   10      


<210>  123
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRL1 (IMGT)

<400>  123

Glu Asn Val Asp Thr Tyr 
1               5       


<210>  124
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRL2 (Kabat, AbM)

<400>  124

Gly Ala Ser Asn Arg Tyr Thr 
1               5           


<210>  125
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab & Anti-IL17A Clone AIN457 - 
       Secukinumab - CDRL2 (IMGT)

<400>  125

Gly Ala 
1       


<210>  126
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IFNy HuZAF - Fontolizumab - CDRL3 (Kabat, AbM, IMGT)

<400>  126

Gly Gln Ser Tyr Asn Tyr Pro Phe Thr 
1               5                   


<210>  127
<211>  127
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab VH

<400>  127

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Ala Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Gly Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Val Arg Asp Tyr Tyr Asp Ile Leu Thr Asp Tyr Tyr Ile His Tyr Trp 
            100                 105                 110         


Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 125         


<210>  128
<211>  109
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab VL

<400>  128

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


Cys Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg 
            100                 105                 


<210>  129
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRH1 (Kabat)

<400>  129

Asn Tyr Trp Met Asn 
1               5   


<210>  130
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRH1 (AbM)

<400>  130

Gly Phe Thr Phe Ser Asn Tyr Trp Met Asn 
1               5                   10  


<210>  131
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRH1 (IMGT)

<400>  131

Gly Phe Thr Phe Ser Asn Tyr Trp 
1               5               


<210>  132
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRH2 (Kabat)

<400>  132

Ala Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Gly Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  133
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRH2 (AbM)

<400>  133

Ala Ile Asn Gln Asp Gly Ser Glu Lys Tyr 
1               5                   10  


<210>  134
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRH2 (IMGT)

<400>  134

Ile Asn Gln Asp Gly Ser Glu Lys 
1               5               


<210>  135
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRH3 (Kabat, AbM)

<400>  135

Asp Tyr Tyr Asp Ile Leu Thr Asp Tyr Tyr Ile His Tyr Trp Tyr Phe 
1               5                   10                  15      


Asp Leu 
        


<210>  136
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRH3 (IMGT)

<400>  136

Val Arg Asp Tyr Tyr Asp Ile Leu Thr Asp Tyr Tyr Ile His Tyr Trp 
1               5                   10                  15      


Tyr Phe Asp Leu 
            20  


<210>  137
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRL1 (Kabat, AbM)

<400>  137

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 
1               5                   10          


<210>  138
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRL1 (IMGT)

<400>  138

Gln Ser Val Ser Ser Ser Tyr 
1               5           


<210>  139
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRL2 (Kabat, AbM)

<400>  139

Gly Ala Ser Ser Arg Ala Thr 
1               5           


<210>  140
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone AIN457 - Secukinumab - CDRL3 (Kabat, AbM, IMGT)

<400>  140

Gln Gln Tyr Gly Ser Ser Pro Cys Thr 
1               5                   


<210>  141
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab VH

<400>  141

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 
            20                  25                  30          


His Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Val Ile Asn Pro Met Tyr Gly Thr Thr Asp Tyr Asn Gln Arg Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Tyr Asp Tyr Phe Thr Gly Thr Gly Val Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  142
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab VL

<400>  142

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Arg Ser Leu Val His Ser 
            20                  25                  30          


Arg Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ile Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser 
                85                  90                  95      


Thr His Leu Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


<210>  143
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRH1 (Kabat)

<400>  143

Asp Tyr His Ile His 
1               5   


<210>  144
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRH1 (AbM)

<400>  144

Gly Tyr Ser Phe Thr Asp Tyr His Ile His 
1               5                   10  


<210>  145
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRH1 (IMGT)

<400>  145

Gly Tyr Ser Phe Thr Asp Tyr His 
1               5               


<210>  146
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRH2 (Kabat)

<400>  146

Val Ile Asn Pro Met Tyr Gly Thr Thr Asp Tyr Asn Gln Arg Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  147
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRH2 (AbM)

<400>  147

Val Ile Asn Pro Met Tyr Gly Thr Thr Asp 
1               5                   10  


<210>  148
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRH2 (IMGT)

<400>  148

Ile Asn Pro Met Tyr Gly Thr Thr 
1               5               


<210>  149
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRH3 (Kabat, AbM)

<400>  149

Tyr Asp Tyr Phe Thr Gly Thr Gly Val Tyr 
1               5                   10  


<210>  150
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRH3 (IMGT)

<400>  150

Ala Arg Tyr Asp Tyr Phe Thr Gly Thr Gly Val Tyr 
1               5                   10          


<210>  151
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRL1 (Kabat, AbM)

<400>  151

Arg Ser Ser Arg Ser Leu Val His Ser Arg Gly Asn Thr Tyr Leu His 
1               5                   10                  15      


<210>  152
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRL1 (IMGT)

<400>  152

Arg Ser Leu Val His Ser Arg Gly Asn Thr Tyr 
1               5                   10      


<210>  153
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRL2 (Kabat, AbM)

<400>  153

Lys Val Ser Asn Arg Phe Ile 
1               5           


<210>  154
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-IL17A Clone Mab126 - Ixekizumab - CDRL3 (Kabat, AbM, IMGT)

<400>  154

Ser Gln Ser Thr His Leu Pro Phe Thr 
1               5                   


<210>  155
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a CD8 transmembrane domain

<400>  155

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu 
1               5                   10                  15      


Ser Leu Val Ile Thr Leu Tyr Cys 
            20                  


<210>  156
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a IgG4 hinge


<220>
<221>  misc_feature
<222>  (1)..(3)
<223>  Xaa can be any naturally occurring amino acid

<400>  156

Xaa Xaa Xaa 
1           


<210>  157
<211>  282
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a IgD hinge

<400>  157

Arg Trp Pro Glu Ser Pro Lys Ala Gln Ala Ser Ser Val Pro Thr Ala 
1               5                   10                  15      


Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala 
            20                  25                  30          


Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys Glu Lys 
        35                  40                  45              


Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro 
    50                  55                  60                  


Ser His Thr Gln Pro Leu Gly Val Tyr Leu Leu Thr Pro Ala Val Gln 
65                  70                  75                  80  


Asp Leu Trp Leu Arg Asp Lys Ala Thr Phe Thr Cys Phe Val Val Gly 
                85                  90                  95      


Ser Asp Leu Lys Asp Ala His Leu Thr Trp Glu Val Ala Gly Lys Val 
            100                 105                 110         


Pro Thr Gly Gly Val Glu Glu Gly Leu Leu Glu Arg His Ser Asn Gly 
        115                 120                 125             


Ser Gln Ser Gln His Ser Arg Leu Thr Leu Pro Arg Ser Leu Trp Asn 
    130                 135                 140                 


Ala Gly Thr Ser Val Thr Cys Thr Leu Asn His Pro Ser Leu Pro Pro 
145                 150                 155                 160 


Gln Arg Leu Met Ala Leu Arg Glu Pro Ala Ala Gln Ala Pro Val Lys 
                165                 170                 175     


Leu Ser Leu Asn Leu Leu Ala Ser Ser Asp Pro Pro Glu Ala Ala Ser 
            180                 185                 190         


Trp Leu Leu Cys Glu Val Ser Gly Phe Ser Pro Pro Asn Ile Leu Leu 
        195                 200                 205             


Met Trp Leu Glu Asp Gln Arg Glu Val Asn Thr Ser Gly Phe Ala Pro 
    210                 215                 220                 


Ala Arg Pro Pro Pro Gln Pro Gly Ser Thr Thr Phe Trp Ala Trp Ser 
225                 230                 235                 240 


Val Leu Arg Val Pro Ala Pro Pro Ser Pro Gln Pro Ala Thr Tyr Thr 
                245                 250                 255     


Cys Val Val Ser His Glu Asp Ser Arg Thr Leu Leu Asn Ala Ser Arg 
            260                 265                 270         


Ser Leu Glu Val Ser Tyr Val Thr Asp His 
        275                 280         


<210>  158
<211>  42
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a 4-1BB co-stimulatrory 
       intracellular signalling domain

<400>  158

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met 
1               5                   10                  15      


Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe 
            20                  25                  30          


Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 
        35                  40          


<210>  159
<211>  48
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exmplary amino acid sequence of a CD27 co-stimulatory 
       intracellular signalling domain

<400>  159

Gln Arg Arg Lys Tyr Arg Ser Asn Lys Gly Glu Ser Pro Val Glu Pro 
1               5                   10                  15      


Ala Glu Pro Cys Arg Tyr Ser Cys Pro Arg Glu Glu Glu Gly Ser Thr 
            20                  25                  30          


Ile Pro Ile Gln Glu Asp Tyr Arg Lys Pro Glu Pro Ala Cys Ser Pro 
        35                  40                  45              


<210>  160
<211>  459
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a CAR comprising IFN-gamma scFv 
       TII 2G1G7, a IgG4 hinge region, a CD28 transmembrane domain, a 
       CD28 co-stimulatory domain, and a CD3 zeta signalling domain 
       (with leader sequence)

<400>  160

Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 
1               5                   10                  15      


His Ala Ala Arg Pro Gln Val Lys Leu Glu Gln Ser Gly Pro Gly Leu 
            20                  25                  30          


Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe 
        35                  40                  45              


Ser Leu Thr Ser Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly Lys 
    50                  55                  60                  


Gly Leu Glu Trp Leu Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr 
65                  70                  75                  80  


Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys 
                85                  90                  95      


Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala 
            100                 105                 110         


Met Tyr Tyr Cys Ala Arg Arg Asp Gly Asn Arg Tyr Tyr Thr Met Asp 
        115                 120                 125             


Tyr Trp Gly Gln Gly Ala Ser Val Thr Val Ser Ser Gly Gly Gly Gly 
    130                 135                 140                 


Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Asn Val Leu Thr 
145                 150                 155                 160 


Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met 
                165                 170                 175     


Thr Cys Arg Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr 
            180                 185                 190         


Gln Gln Lys Ser Gly Gly Ser Pro Lys Leu Trp Ile Tyr Arg Thr Ser 
        195                 200                 205             


Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 
    210                 215                 220                 


Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala 
225                 230                 235                 240 


Thr Tyr Tyr Cys Gln Gln Tyr Ser Gly Tyr Pro Leu Thr Phe Gly Ala 
                245                 250                 255     


Gly Thr Lys Leu Glu Leu Lys Arg Ala Ser Ala Glu Ser Lys Tyr Gly 
            260                 265                 270         


Pro Pro Cys Pro Pro Cys Pro Phe Trp Val Leu Val Val Val Gly Gly 
        275                 280                 285             


Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe 
    290                 295                 300                 


Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn 
305                 310                 315                 320 


Met Thr Pro Arg Arg Leu Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr 
                325                 330                 335     


Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser 
            340                 345                 350         


Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr 
        355                 360                 365             


Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys 
    370                 375                 380                 


Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn 
385                 390                 395                 400 


Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu 
                405                 410                 415     


Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 
            420                 425                 430         


His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 
        435                 440                 445             


Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 
    450                 455                 


<210>  161
<211>  460
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of CAR PMC882 comprising the TNF 
       alpha scFv, a CD28 hinge, a CD28 transmembrane domain, a CD28 
       co-stimulatory domain, and a CD3 zeta signalling domain (without 
       leader sequence)

<400>  161

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ser Ile Ser Ser Thr Gly Ala Ser Thr Thr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Gly Gly Ala Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
        115                 120                 125             


Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala 
    130                 135                 140                 


Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile 
145                 150                 155                 160 


Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys 
                165                 170                 175     


Leu Leu Ile Tyr Ser Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg 
            180                 185                 190         


Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 
        195                 200                 205             


Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Asn 
    210                 215                 220                 


Ala Pro Thr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ser 
225                 230                 235                 240 


Ala Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser 
                245                 250                 255     


Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro 
            260                 265                 270         


Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly 
        275                 280                 285             


Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile 
    290                 295                 300                 


Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met 
305                 310                 315                 320 


Asn Met Thr Pro Arg Arg Leu Gly Pro Thr Arg Lys His Tyr Gln Pro 
                325                 330                 335     


Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe 
            340                 345                 350         


Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu 
        355                 360                 365             


Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp 
    370                 375                 380                 


Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys 
385                 390                 395                 400 


Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala 
                405                 410                 415     


Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys 
            420                 425                 430         


Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr 
        435                 440                 445             


Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 
    450                 455                 460 


<210>  162
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone P3H2 VH

<400>  162

Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 
1               5                   10                  15      


Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser 
            20                  25                  30          


Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Val Ser Ser Ile Ser Ser Thr Gly Ala Ser Thr Thr Tyr Ala Asp Ser 
    50                  55                  60                  


Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu 
65                  70                  75                  80  


Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Lys Gly Gly Ala Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  163
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Anti-TNFa scFv clone P3H2 VL

<400>  163

Thr Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val 
1               5                   10                  15      


Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser 
            20                  25                  30          


Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Ser Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Asn Ala Pro 
                85                  90                  95      


Thr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ala Ala Ala 
            100                 105                 110         


<210>  164
<211>  78
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a CD8a hinge

<400>  164

Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 
1               5                   10                  15      


Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 
            20                  25                  30          


Phe Pro Gly Pro Ser Lys Pro Ile Glu Val Met Tyr Pro Pro Pro Tyr 
        35                  40                  45              


Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys 
    50                  55                  60                  


His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro 
65                  70                  75              


<210>  165
<211>  438
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a CAR comprising IFN-gamma scFv 
       TII 2G1G7, a IgG4 hinge region, a CD28 transmembrane domain, a 
       CD28 co-stimulatory domain, and a CD3 zeta signalling domain 
       (without leader sequence)

<400>  165

Gln Val Lys Leu Glu Gln Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Arg Asp Gly Asn Arg Tyr Tyr Thr Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Ala Ser Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 
        115                 120                 125             


Ser Gly Gly Gly Gly Ser Glu Asn Val Leu Thr Gln Ser Pro Ala Ile 
    130                 135                 140                 


Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 
145                 150                 155                 160 


Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly 
                165                 170                 175     


Gly Ser Pro Lys Leu Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly 
            180                 185                 190         


Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu 
        195                 200                 205             


Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln 
    210                 215                 220                 


Gln Tyr Ser Gly Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu 
225                 230                 235                 240 


Leu Lys Arg Ala Ser Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro 
                245                 250                 255     


Cys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr 
            260                 265                 270         


Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys 
        275                 280                 285             


Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg 
    290                 295                 300                 


Leu Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp 
305                 310                 315                 320 


Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 
                325                 330                 335     


Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 
            340                 345                 350         


Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 
        355                 360                 365             


Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 
    370                 375                 380                 


Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 
385                 390                 395                 400 


Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 
                405                 410                 415     


Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 
            420                 425                 430         


Gln Ala Leu Pro Pro Arg 
        435             


<210>  166
<211>  244
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary amino acid sequence of a TNF-alpha scFv clone P3H2 - v2

<400>  166

Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly 
1               5                   10                  15      


Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser 
            20                  25                  30          


Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Val Ser Ser Ile Ser Ser Thr Gly Ala Ser Thr Thr Tyr Ala Asp Ser 
    50                  55                  60                  


Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu 
65                  70                  75                  80  


Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Lys Gly Gly Ala Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
        115                 120                 125             


Gly Gly Gly Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu 
    130                 135                 140                 


Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln 
145                 150                 155                 160 


Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala 
                165                 170                 175     


Pro Lys Leu Leu Ile Tyr Ser Ala Ser Tyr Leu Gln Ser Gly Val Pro 
            180                 185                 190         


Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
        195                 200                 205             


Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala 
    210                 215                 220                 


Asn Asn Ala Pro Thr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
225                 230                 235                 240 


Arg Ala Ala Ala 
                


